| pubmed-article:8838183 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8838183 | lifeskim:mentions | umls-concept:C0001175 | lld:lifeskim |
| pubmed-article:8838183 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8838183 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8838183 | lifeskim:mentions | umls-concept:C0014038 | lld:lifeskim |
| pubmed-article:8838183 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:8838183 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:8838183 | lifeskim:mentions | umls-concept:C0449435 | lld:lifeskim |
| pubmed-article:8838183 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8838183 | pubmed:dateCreated | 1996-12-3 | lld:pubmed |
| pubmed-article:8838183 | pubmed:abstractText | This European multicenter study compares the efficacy and tolerance of the combination of pyrimethamine-clindamycin (Pyr-Cm) with the standard therapy pyrimethamine-sulfadiazine (Pyr-Sdz) for the treatment of toxoplasmic encephalitis (TE) in patients with AIDS. Two hundred ninety-nine human immunodeficiency virus-infected patients with TE were randomly assigned to receive 50 mg of pyrimethamine daily combined with either 2,400 mg of clindamycin or 4 g of sulfadiazine for 6 weeks followed by maintenance therapy with 25 mg of pyrimethamine daily with either 1,200 mg of clindamycin or 2 g of sulfadiazine. An intent-to-treat analysis showed that Pyr-Cm was less effective than Pyr-Sdz; the overall risk of progression of TE was 1.84 times higher for patients receiving Pyr-Cm therapy. There was no statistically significant difference in efficacy during acute therapy, although the rate of crossover motivated by a lack of response was higher among Pyr-Cm recipients. The difference in efficacy was evidenced during the maintenance phase of treatment; the relapse rate was twice as high among patients in the Pyr-Cm group (P = .02). The rate of side effects due to both regimens was similar, although the toxic effects of Pyr-Cm led to fewer discontinuations of therapy than did those of Pyr-Sdz (11% vs. 30%, respectively; P = .001). Pyr-Sdz appears to be the most effective treatment of TE. Pyr-Cm is a valuable alternative but is less effective for long-term prevention of relapses. | lld:pubmed |
| pubmed-article:8838183 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8838183 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8838183 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8838183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8838183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8838183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8838183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8838183 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8838183 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8838183 | pubmed:issn | 1058-4838 | lld:pubmed |
| pubmed-article:8838183 | pubmed:author | pubmed-author:ClumeckNN | lld:pubmed |
| pubmed-article:8838183 | pubmed:author | pubmed-author:KatlamaCC | lld:pubmed |
| pubmed-article:8838183 | pubmed:author | pubmed-author:De WitSS | lld:pubmed |
| pubmed-article:8838183 | pubmed:author | pubmed-author:O'DohertyEE | lld:pubmed |
| pubmed-article:8838183 | pubmed:author | pubmed-author:Van GlabekeMM | lld:pubmed |
| pubmed-article:8838183 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8838183 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:8838183 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8838183 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8838183 | pubmed:pagination | 268-75 | lld:pubmed |
| pubmed-article:8838183 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:meshHeading | pubmed-meshheading:8838183-... | lld:pubmed |
| pubmed-article:8838183 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8838183 | pubmed:articleTitle | Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. | lld:pubmed |
| pubmed-article:8838183 | pubmed:affiliation | Department of Infectious Diseases and Tropical Medicine, Pitié-Salpêtrière Hospital, Paris, France. | lld:pubmed |
| pubmed-article:8838183 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8838183 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8838183 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8838183 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8838183 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:8838183 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8838183 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8838183 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8838183 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8838183 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8838183 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8838183 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8838183 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8838183 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8838183 | lld:pubmed |
